Despite these promising clinical outcomes of anti-BCMA CAR T-cell therapy in R/R- MM, some subsets of patients are still at risk of relapse during this treatment, which has become another focus of attention. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.